Hemoglobin value effects of levosimendan in patients with heart failure complicating an acute coronary syndrome

11 May 2024 (08:00 - 20:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Mr Antonio Rocha De Almeida

Hospital Espirito Santo de Evora, Evora (Portugal)

4 More presentations in this session

Presentation thumbnail

Doxorubicin leads to increased oxidative stress and opening of the calcium-induced mitochondrial permeability transition pore

Mrs M. Denysova (Kiev, UA)

Abstract Slides Video

Presentation thumbnail

The impact of STR in impedance cardiography on cardiovascular mortality among heart failure patients with reduced ejection fraction

Professor S. Charfeddine (Sfax, TN)

Abstract Slides

Presentation thumbnail

Fontan survivors and left ventricular dysfunction in adult patients

Doctor M. Carvalho (Leiria, PT)

Abstract Slides Video

Presentation thumbnail

Spot urinary sodium and its relation to reverse remodelling in new onset heart failure with reduced EF

Doctor M. Ibrahim (Cairo, EG)

Abstract Slides Video

Access the full session

Session thumbnail

ePosters in chronic heart failure - pathophysiology and mechanisms 2

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024

You may be interested in

Congress Presentation

Changes in hemodynamic, strain and myocardial work parameters predict long term mortaility and rehospitalization in acute, decompensated heart failure after levosimendan administration.

Congress Presentation

Impact of anemia on long-term clinical outcomes in patients with acute myocardial infarction accompanied by cardiogenic shock

Congress Presentation

Levosimendan in patients with cardiogenic shock refractory to dobutamine weaning

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources